{"id":"dexamethasone-plus-radium-223","safety":{"commonSideEffects":[{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Immunosuppression (from dexamethasone)"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Radium-223 is an alpha-emitting radioisotope that localizes to bone and delivers high-energy radiation directly to metastatic lesions, causing DNA damage and cell death in bone-seeking cancers. Dexamethasone, a corticosteroid, is added to reduce inflammation and potentially mitigate radiation-induced inflammatory responses. This combination targets castration-resistant prostate cancer with bone metastases.","oneSentence":"Dexamethasone reduces inflammation and immune response while Radium-223 delivers targeted alpha radiation to bone metastases to kill cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:44:28.727Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Castration-resistant prostate cancer with bone metastases"}]},"trialDetails":[{"nctId":"NCT03432949","phase":"PHASE4","title":"Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2018-02-23","conditions":"Metastatic Prostate Cancer","enrollment":24},{"nctId":"NCT02928029","phase":"PHASE1, PHASE2","title":"Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma","status":"TERMINATED","sponsor":"Bayer","startDate":"2017-02-10","conditions":"Multiple Myeloma","enrollment":7},{"nctId":"NCT01106352","phase":"PHASE1, PHASE2","title":"A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-07","conditions":"Bone Metastases, Castration-Resistant Prostate Cancer","enrollment":70},{"nctId":"NCT02605356","phase":"PHASE1, PHASE2","title":"Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2016-10","conditions":"Multiple Myeloma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dexamethasone","Baycadron"],"phase":"marketed","status":"active","brandName":"Dexamethasone plus Radium-223","genericName":"Dexamethasone plus Radium-223","companyName":"University Health Network, Toronto","companyId":"university-health-network-toronto","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dexamethasone reduces inflammation and immune response while Radium-223 delivers targeted alpha radiation to bone metastases to kill cancer cells. Used for Castration-resistant prostate cancer with bone metastases.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}